Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
Plos One
|
March 31, 2015
Properties of neurons derived from induced pluripotent stem cells of Gaucher disease type 2 patient fibroblasts: potential role in neuropathology
Ying Sun, Jane Florer, Christopher N Mayhew, et al.
Human Molecular Genetics
|
January 6, 2010
Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits
Ying Sun, Benjamin Liou, Huimin Ran, et al.
Human Molecular Genetics
|
September 23, 2016
Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease mice
Benjamin Liou, Yanyan Peng, Ronghua Li, et al.
Nature
|
February 23, 2017
Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease
Manoj K Pandey, Thomas A Burrow, Reena Rani, et al.
Human Molecular Genetics
|
October 1, 2015
Neuronopathic Gaucher disease: dysregulated mRNAs and miRNAs in brain pathogenesis and effects of pharmacologic chaperone treatment in a mouse model
Nupur Dasgupta, You-Hai Xu, Ronghua Li, et al.
ACS Chemical Neuroscience
|
October 9, 2020
Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors as Substrate Reduction Therapy for Gaucher Disease Type 3
Michael W Wilson, Liming Shu, Vania Hinkovska-Galcheva, et al.
Biorxiv : the Preprint Server for Biology
|
November 24, 2025
Patient-Specific Midbrain Organoids with CRISPR Correction Reveal Disease Mechanisms and Enable Therapeutic Evaluation in Neuronopathic Gaucher Disease
Yi Lin, Benjamin Liou, Venette Fannin, et al.
Elife
|
June 23, 2026
Patient-specific midbrain organoids with CRISPR correction recapitulate neuronopathic Gaucher disease phenotypes and enable evaluation of novel therapies
Yi Lin, Benjamin Liou, Venette Fannin, et al.
Neurotoxicology
|
June 10, 2017
The effect of manganese exposure in Atp13a2-deficient mice
Sheila M Fleming, Nicholas A Santiago, Elizabeth J Mullin, et al.
Science Translational Medicine
|
March 16, 2022
Treatment of a genetic brain disease by CNS-wide microglia replacement
Yohei Shibuya, Kevin K Kumar, Marius Marc-Daniel Mader, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
Plos One
|
March 31, 2015
Properties of neurons derived from induced pluripotent stem cells of Gaucher disease type 2 patient fibroblasts: potential role in neuropathology
Ying Sun, Jane Florer, Christopher N Mayhew, et al.
Human Molecular Genetics
|
January 6, 2010
Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits
Ying Sun, Benjamin Liou, Huimin Ran, et al.
Human Molecular Genetics
|
September 23, 2016
Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease mice
Benjamin Liou, Yanyan Peng, Ronghua Li, et al.
Nature
|
February 23, 2017
Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease
Manoj K Pandey, Thomas A Burrow, Reena Rani, et al.
Human Molecular Genetics
|
October 1, 2015
Neuronopathic Gaucher disease: dysregulated mRNAs and miRNAs in brain pathogenesis and effects of pharmacologic chaperone treatment in a mouse model
Nupur Dasgupta, You-Hai Xu, Ronghua Li, et al.
ACS Chemical Neuroscience
|
October 9, 2020
Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors as Substrate Reduction Therapy for Gaucher Disease Type 3
Michael W Wilson, Liming Shu, Vania Hinkovska-Galcheva, et al.
Biorxiv : the Preprint Server for Biology
|
November 24, 2025
Patient-Specific Midbrain Organoids with CRISPR Correction Reveal Disease Mechanisms and Enable Therapeutic Evaluation in Neuronopathic Gaucher Disease
Yi Lin, Benjamin Liou, Venette Fannin, et al.
Elife
|
June 23, 2026
Patient-specific midbrain organoids with CRISPR correction recapitulate neuronopathic Gaucher disease phenotypes and enable evaluation of novel therapies
Yi Lin, Benjamin Liou, Venette Fannin, et al.
Neurotoxicology
|
June 10, 2017
The effect of manganese exposure in Atp13a2-deficient mice
Sheila M Fleming, Nicholas A Santiago, Elizabeth J Mullin, et al.
Science Translational Medicine
|
March 16, 2022
Treatment of a genetic brain disease by CNS-wide microglia replacement
Yohei Shibuya, Kevin K Kumar, Marius Marc-Daniel Mader, et al.
Page
of 4